Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Dagra Pharmaceuticals
Diemen, North Holland, Netherlands
- Ownership
- Private
- Development stage
- Other
01
Overview
Dagra Pharmaceuticals is a historical Dutch pharmaceutical company, originally founded as Dagra NV in 1932 and based in Diemen, Netherlands. The company specialized in the development and manufacture of vitamins, hormone replacement therapies, and diagnostic imaging agents, with well-known brands such as Dagravit and Dagynil. Following its acquisition by Byk Gulden (Altana) in 1982, the company passed through several owners, including ASTA Medica and Meda, before eventually becoming part of Viatris. While the original legal entity has been integrated into larger corporate structures, the Dagra name and its product portfolio remain active in various international markets, particularly in the Middle East and Europe.
- Therapeutic areas
- EndocrinologyWomen's HealthGastroenterologyMetabolic Disorders
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on Dagra Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dagra Pharmaceuticals.